BioPharma Bitez: AstraZeneca, Axovant, and more!

Welcome back everybody to another edition of “BioPharma Bitez,” the top news in the industry as well as one story outside of it. So, to kick things off this week, AbbVie has boosted its, “multiple myeloma” program with a new million dollar in “teneobio” who specializes in heavy chain antibodies.… Read more

BioPharma Bitez: Alkermes, Merck, UniQure, and more!

Welcome back everybody to another edition of “BioPharma Bitez” the top news in the industry as well as one story outside of it. So, kicking things off, Alkermes says, and LCFD has rejected the NDA for their top-of-the-line depression drug this past week. GSK is now co-developing a fusion protein… Read more

BioPharma Bitez: Roche, Voyage, UK Biotechs and more!

Welcome back everybody to another edition of “BioPharma Bitez” the top news in the industry as well as one story outside of it. So, kicking things off in the past week, UK Biotechs had a record year of vesting with over 1.1 billion pounds which is about 1.44 billion dollars vested… Read more

BioPharma Bitez: Celgene, CRISPR, Editas and more!

Welcome back everybody to another edition of “BioPharma Bitez,” the top news in the industry as well as one story outside of it. And stick around to for a new segment that I have added on. So, to kick it off this week, Celgene continues their deal-making campaign with Kyn… Read more

BioPharma Bitez: Verona, Aptinyx, and more!

Happy Friday everybody, welcome to this week’s edition of “BioPharma Bitez.” Top news in the industry as well as one story outside of it. Now, with a new, shinier, backdrop! So, to kick it off this week, Verona suffered a “phase two failure” for a COPD bronchodilator product. It would… Read more

BioPharma Bitez: Novartis, Takeda and more!

Happy Friday everybody, welcome to this week’s edition of “BioPharma Bitez.” The tops news in the industry as well as one story outside of it. So, obviously, J.P. Morgan was this week, so, some of the stories that came out of that: Eli Lilly has bought Loxo for 8 billion… Read more

BioPharma Bitez: GSK, Vanda, Abbvie, and more!

Happy Friday everybody! Welcome to this week’s edition of “BioPharma Bitez”, the top news of the industry as well as one outside of it. So, to kick it off this week, the obvious story is GSK buying Tesaro for 5 billion dollars. This will actually expand GSK’s commercial oncology portfolio. We… Read more

The Value of Trade shows

 I wanted to continue the discussion with effective marketing strategies. All of these tips should be used in tandem. So, we’ve got “MPC marketing” finding those impact players, critically important. Building your brand through social media, doing a post, just getting active in those areas. Do more today than… Read more

BioPharma Bitez: Nestle, Moderna, and Stan Lee

Happy Friday everybody. Welcome to this week’s edition of “BioPharma Bitez.” Top news in the industry as well as one story outside of it. So, to kick it off this week, Nestle has increased their stake in Aimmune’s Peanut Allergy medication portfolio up to 276 million dollars with their investment.… Read more

BioPharma Bitez: AstraZeneca, Biogen, and more!

Happy Friday everybody, welcome to this week’s episode of “BioPharma Bitez,” the top news of the industry, as well as one interesting story outside of it. So, to kick it off, Bain Capital announced this week they’re going to back a start-up called “Cerevel” which is a neuroscience-based pipeline that… Read more